Coherus Q2: LOQTORZI Is Climbing, But the $105 Million Cash Runway Keeps CHRS a Binary Bet

LOQTORZI sales are improving, but the cash cushion still sets the timeline

This quarter was more of a commercial update than a clinical one. The central tension is straightforward: LOQTORZI Q2 net sales rose 15% to $13.6 million, while Coherus still ended the quarter with $105.3 million in cash, cash equivalents, and investments. Investors are not judging a finished franchise. They are judging whether sales can keep climbing before the cash cushion gets thinner.

Management said demand trends remained strong in the second quarter, and Full-Year 2026 LOQTORZI Revenue Guidance: Expected to be between $57 million and $62 million still implies stronger sales from here. Bears, meanwhile, are focused on the cash drawdown: Coherus went from $167 million at Q1 2026 to $105.3 million at end of Q2 2026. So the stock still feels like a race between commercial momentum and funding needs.

Why the patient ramp matters more than the headline sales number

More patients can become more cash - and more options

The key question is not whether LOQTORZI has a rationale. It is whether patient growth can translate into enough revenue to give Coherus real strategic room. The company's plan is to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance the development of new indications for LOQTORZI in combination, while also pursuing pipeline partnerships and synergies from proprietary combinations.

That is why this quarter mattered beyond the $13.6 million sales line. Coherus reported the highest number of new patient starts since launch and said demand trends remained strong. If that pattern holds, the business has a cleaner path to steadier prescribing, longer treatment duration, and better odds of funding the next milestone without rushing to raise capital.

The first-half trend improved, but it is still early

H1 results also improved. Coherus generated $26.6 million in net revenue in the first half of 2026, compared with $17.9 million a year earlier. At the same time, spending declined: R&D Expense: $21.4 million in Q2 2026, down from $26.3 million in Q2 2025 and SG&A Expense: $21.0 million in Q2 2026, down from $26.0 million in Q2 2025.

That combination matters. Higher revenue and lower spending leave more cash on the balance sheet, which improves the odds that LOQTORZI can help fund pipeline progress rather than simply offset it.

The pipeline still needs stronger proof

Why the October data disclosure matters

The biggest risk is that the pipeline is still only early. Tagmokitug showed emerging evidence of clinical activity in combination with toripalimab in HNSCC, but that is not the same as established, commercial-grade evidence. Coherus itself said it expects a projected October public disclosure of data sets with sufficient maturity, which makes the next reporting window important.

If the October data strengthen the combination case, the company gains a more credible path to partnership value and a higher valuation floor. If not, the market may conclude the cash cushion is mainly buying time rather than confirming a broader story.

What would confirm or break the setup from here

This is still a short-to-medium-term execution story rather than a proven long-term compounder. Coherus has $105.3 million in cash, cash equivalents, and investments and previously said it had a cash runway through 2026. It also has a projected October public disclosure of data sets with sufficient maturity. What happens around those milestones will do most of the work for the stock.

What would confirm the bull case

• The October disclosure shows data that are stronger than early signals and support the combination thesis beyond HNSCC anecdotes.
• The next commercial update still shows solid patient initiation and demand trends, supporting the case for continued sales progress.
• Management can keep the 2026 sales path credible against Full-Year 2026 LOQTORZI Revenue Guidance: Expected to be between $57 million and $62 million.

What would pressure the thesis

• Sales momentum slows enough that the market sees the cash cushion as buying time rather than funding an accelerating business.
• The October data do not strengthen the combination story beyond emerging evidence of clinical activity in combination with toripalimab in HNSCC.
• Management stops framing financing around milestones and starts signaling closer capital needs instead.

For now, the setup is fundable but binary. $105.3 million in cash, cash equivalents, and investments gives Coherus room for the next tests, and it previously described a cash runway through 2026. But until LOQTORZI converts patient growth into a steadier revenue ramp and the pipeline adds stronger evidence, CHRS still looks more like an execution trade than a fully de-risked long-term story.